Whenever a new infectious disease enters the scene (or reenters, as in the case of measles), developing precise and accurate diagnostic tests as quickly as possible is critical. In this interview, Dr. Ben Bradley, ARUP medical director of the Institute for Research and Innovation in Infectious Disease Genomic Technologies, High Consequence Pathogen Response, Virology, and Molecular Infectious Diseases, describes various challenges in rapidly setting up and maintaining testing capacity for these kinds of diseases and why we need collaboration between academic, clinical, and public health labs.

Webinar: Emerging Viral Diseases: A 2025 Update for Laboratorians [https://arup.utah.edu/education/bradley-emergingviral-2025.php]; Measles by Real-Time PCR: A Rapid and Reliable Method for Measles Testing [https://www.youtube.com/watch?v=NZdZDPv-oTw]

In this age of algorithms, how do we ensure clinical care is both science based and personalized? In this interview, Dr. Ryan Metcalf, section chief of Transfusion Medicine at ARUP Laboratories and University of Utah Health and associate professor of Pathology at the University of Utah School of Medicine, shares the story behind the new platelet transfusion guideline from the Association for the Advancement of Blood and Biotherapies (AABB). He describes how the authors addressed patient-specific variation and the inherent uncertainty of scientific evidence.

Related Information:

• Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines [https://arup.utah.edu/education/metcalf-platelet-2025.php/]
• JAMA® Article: Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines [https://jamanetwork.com/journals/jama/fullarticle/2834703]
• JAMA® Clinical Reviews Podcast: Platelet Transfusion: Best Practice Guidelines [https://edhub.ama-assn.org/jn-learning/audio-player/18977738]

Health equity and personalized medicine share a common goal: tailoring care to the needs of each individual. In this interview, Dr. Octavia Peck Palmer from the University of Pittsburgh Medical Center, immediate past president of ADLM, explains how diversity is foundational to advancing clinical science and improving patient outcomes.

After nearly dying from a mysterious disease during medical school, Dr. David Fajgenbaum dedicated his career to breaking down barriers in biomedical research. Fajgenbaum is now an associate professor of medicine at the University of Pennsylvania and cofounder of Every Cure. In this conversation, we discuss his personal diagnostic journey and the errors and delays he encountered along the way. We also explore why academic medicine needs to go beyond generating disparate pieces of scientific knowledge and instead turn that information into nodes on a network that spans specialty silos to speed the discovery of effective treatments.

Every specimen represents a potential mystery, and laboratory professionals often play the role of detectives. For the 2025 Lab Week episode of LabMind, Amanda Openshaw, a genetic counselor at ARUP, shares examples illustrating the importance of good investigative work in the laboratory to discover accurate diagnoses.

Why hasn’t there been more progress in developing therapies for Alzheimer’s disease and related forms of dementia? One reason has been the lack of specific laboratory tests that can properly diagnose and characterize these diseases. In this interview, Dr. Qinwen Mao from the University of Utah describes how her research team is helping to bring new blood and cerebrospinal fluid biomarkers into clinical practice to step up the fight against these devastating diseases.

Related Information: Webinar: Innovations in Diagnostics for Alzheimer’s Disease and Related Dementias (aruplab.com/AlzInnovations)

As laboratory professionals, we may think we have a good understanding of how physicians use our services. But how often do we ask them for practical feedback? In this interview, family physician Dr. Keith Elkins shares his perspectives on what clinical laboratories and pathologists do well, and what opportunities they may be overlooking to better support frontline clinical care.

Many people in the healthcare profession know that clinical laboratories are under more rigorous regulatory scrutiny than just about any other area of medicine. What they may not know is that the New York State Department of Health (NY DOH) was the pioneer in laboratory regulation, starting long before the implementation of either the FDA Medical Device Amendments or the Clinical Laboratory Improvement Amendments (CLIA) of 1988. In this interview, Beverly Rauch, MS, director of the NY DOH’s Clinical Laboratory Evaluation Program (NY CLEP), describes its process for granting permits, inspecting laboratories, and approving assays, and what the new FDA LDT rule might mean for the program.